Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Viral Vector
Sort By
Newest First
1 / 3
1 / 3
Sign in
Nonviral Delivery
Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery using dbDNA
Lisa Caproni
Touchlight
PAO-12-24-CL-4
Dec 16, 2024
Cell and Gene Therapy Regulatory
Navigating Regulatory Complexity for Cell and Gene Therapies
Natasha Rivas
PAO-04-24-CL-03
Apr 12, 2024
Viral Vectors
A Viral Vector CDMO Vision that Resonates
Drew Brennan; Chris Berger; Elie Hanania, Ph.D.; Dave Ingamells; Rami Barghout, PE
Avid Bioservices
PAO-03-24-CL-06
Mar 14, 2024
Plasmid Manufacturing
Optimizing Plasmid Production to Meet Growing Demand
Cynthia A. Challener, Ph.D.; Danielle Alvarez
Pharma's Almanac
PAO-04-23-NI-01
Apr 03, 2023
Viral Vector Manufacturing
Considerations in Viral Vector Analytical Development to Enable Smooth Transfer to Quality Control
Chris Berger; Kilian Witzel
Avid Bioservices
PAO-02-23-CL-03
Mar 14, 2023
Viral Vector Manufacturing
Optimizing Transient Transfection for Viral Vector Production
Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.
Pharma's Almanac
PAO-11-022-NI-09
Nov 15, 2022
Viral Vectors
Risk-Based Optimization of Viral Vector Processes Adds Real Value
Elie Hanania, Ph.D.; Tatiana Mello, M.S.
Avid Bioservices
PAO-09-022-CL-05
Oct 25, 2022
Cell and Gene Therapy
State of the Cell and Gene Therapy Market
James Grote
Nice Insight
PAO-10-022-NI-01
Oct 11, 2022
Cell and Gene Therapy Analytics
Accelerating the Development of High-Quality Cell and Gene Therapies with Comprehensive, In-house Analytical Support
Hui Chen, Ph.D.
Porton Advanced Solutions
PAO-06-022-CL-07
Jun 21, 2022
Viral Vector Manufacturing
Avid Bioservices, Inc. and CRB Highlight Efforts that Enabled Opening of First Phase of New Viral Vector Facility in California in Only Eight Months
Avid Bioservices
PR-M06-22-05
Jun 16, 2022
New Facility
AGC Biologics Invests in Viral Vector Suspension at New U.S. Campus
AGC Biologics
PR-M05-22-13-359
May 18, 2022
Viral Vector Manufacturing
Approaching Viral Vector Manufacturing With an Emphasis on Quality and Design
Chris Berger; Atef Khezri
Avid Bioservices
PAO-05-022-CL-02
May 10, 2022
Gene Therapy Analytics
Overcoming Analytical Challenges for Gene Therapies
Jennifer Chadwick, Ph.D.
ProtaGene
PAO-02-022-CL-14
Mar 20, 2022
Viral Vector Manufacturing
Optimizing Yields, Tech Transfer, and the Supply Chain for Viral Vector Manufacturing
Andrew Moreo; Lenore Giannunzio
Andelyn Biosciences
PAO-02-022-CL-01
Mar 12, 2022
Vaccines
100 Years in Vaccines and Looking Toward the Future
IDT Biologika
PAO-01-22-R250-13
Jan 28, 2022
2021 Roundup: The Year of Cell and Gene Therapy
David Alvaro, Ph.D.
Pharma's Almanac
PA734
Dec 20, 2021
Viral Vaccines
Viral Vectors, Vaccines — A New Era Of Collaborative Design
Andreas Neubert, Ph.D.
IDT Biologika
PAO-10-21-CL-17
Nov 08, 2021
Cell and Gene Therapy
Coping with a Talent Shortage and Talent War in Cell and Gene Therapy
Cyrill Kellerhals; Sarah O'Reilly
Andelyn Biosciences
PAO-10-21-CL-12
Oct 26, 2021
Gene Therapy
A Customer-Centric Approach to Cell and Gene Therapy Manufacturing
Drew Brennan
Avid Bioservices
PAO-10-21-CL-06
Oct 13, 2021
Viral Vectors
Navigating Analytical Requirements for GMP Viral Vectors
Will Fountain
Andelyn Biosciences
PAO-10-21-CL-02
Oct 08, 2021
